The translocation of drugs across biological membranes not only occurs via passive diŠusion but also by transporter-mediated processes. Knowledge of tissue-speciˆc drug transporter expression, as well as characterization of substrate drugs of individual transporters, leads to a better understanding of the role of these transporters in the pharmacokinetics of drugs. The ATP-binding cassette transporter family member breast cancer resistance protein (BCRP) is one of the most important intestinal eOEux transporters involved in the intestinal absorption or permeability of drugs. A genetic variant in the BCRP, 421C＞A, is a useful biomarker for explaining large interindividual diŠerences in the pharmacokinetics of sulfasalazine (SASP), a BCRP substrate. However, large intragenotypic diŠerences remain in spite of the incorporation of this genotype into the pharmacokinetics of SASP. Epigenetic regulation alters gene expression without changing DNA sequences. In epigenetic regulation, microRNAs (miRNAs) appear to be the most extensively investigated due to their important roles in the posttranscriptional regulation of mRNAs. Our study showed that miR-328 negatively regulates BCRP expression in human tissues, and the intestine-derived exosomal miR-328 levels positively correlated with the SASP area under the blood concentration-time curve. These results suggest that circulating intestinederived exosomal miR-328 in plasma has potential as a possible biomarker for estimating BCRP function in human intestines. A clearer understanding of epigenetic mechanisms regulating the expression of drug transporters will provide insights into novel approaches to individualized drug therapy.
Upward arrows indicate an increase in mRNA or protein expression. Downward arrows indicate a decrese in mRNA or protein expression. 
